The endothelium is recognized today as a functional and dynamic component of the body that plays an important part in health and disease. This article briefly reviews the role ofendothelium in thrombosis and hemostasis. There is a paradigm shift from one that regards the endothelium as one single entity to the concept that the endothelium is heterogeneous. Thrombotic complications in many disorders show a predilection to specific locations, despite the fact that a hypercoagulable state affects the entire body. Likewise, bleeding is more commonly encountered in certain anatomical locations than in others. Recent observations of the heterogeneous distribution of coagulation and fibrino lytic factors in the endothelium and the adaptation of the endothelium to various stimuli may provide an explanation for the diverse phenotypes. Recognition of this changing paradigm is helpful to for the diagnosis and management of bleeding and thrombotic complications. It also helps in the understanding of the pathogenesis of many bleeding and thrombotic disorders, and in the development of new drug designs for site-specific therapy.
In 1865, Wilhelm His first introduced the term endothelium is a departure from the previously accepted endothelium to describe the mesoderm-derived lining of notion that endothelium is an inert lining and "all internal body cavities. 1 Since then, our perception ofthis endothelial cells are alike." From clinical observations, lining has undergone major changes. The term is now in vitro endothelial cell culture studies as well as in vivo applied solely to the lining of blood vessels and lyrn investigations in animals, it is clear that the endothelium phatics. Its characteristics and functions are also better is heterogeneous, both in its anatomical and functional understood. Along with this new understanding is the characteristics. These observations have been previously realization that the endothelium is a highly metabolic reviewed in detail. [2] [3] [4] [5] [6] [7] [8] In this article, we add new obser and dynamic tissue that is constantly responding to vations that support this concept and show that it also changes in its environment. Endothelial cells play a applies to hemostasis and thrombosis. major role not only in many physiological functions but also in the pathogenesis of many pathological dis orders. Endothelial phenotypes are uniquely adapted to PHYSIOLOGICAL CONDITIONS their local tissue environment. They are influenced by a
The normal endothelium has a large surface of ",350 m 2 wide variety of stimuli ranging from biochemical cues with a mass of ",110 g. 9 The structure of normal (e.g., inflammatory cytokines). This new concept of the endothelium is different in different locations of the body. For example, the endothelium can be continuous with tight junction between cells, as found in the central nervous system, lymph nodes, and muscles; fenestrated, with absorption, secretion, and filtration functions, as seen in endocrine glands, gastrointestinal tract, and kidneys; or discontinuous, where intercellular gaps are 0.1 to 1 ILm in diameter, as seen in the liver sinusoids, bone marrow, and spleen. 9 . 10 As another example, the endothelium in arteries is structurally different from that in the veins. This particular topic is reviewed by T se and Stan in this issue of Seminars in Thrombosis and Hemo
stasis.
ll The endothelium is highly dynamic, adapting to its microenvironment, as affected by spatial and temporal changes in biomechanical and biochemical factors. 12 Further, the endothelium is not simply a passive lining but rather an active participant of many body functions including maintenance of vascular tone, regulating ex change of fluids, and trafficking of cellular components between the intravascular and extravascular compart ments, maintaining fluidity of blood and adapting to changes in the blood flow and fluid dynamics. Changes in its environment can activate the endothelium, as detected by specific markers. Under certain conditions, this response may be exaggerated, causing endothelial dysfunction that ultimately leads to disease.
CLINICAL OBSERVATIONS ON SITE OF THROMBOSIS
Most venous thrombosis occurs in the deep veins of the lower extremities in patients with increased risk factors, which can include hereditary thrombophilia and ac quired hypercoagulable states, ranging from antiphos pholipid syndrome to the adverse effect of drugs such as oral contraceptives. 13 However, thrombotic complica tions in many disorders present themselves in specific locations, as listed in Table 1 . The reasons for this site predilection are not always clear and are reviewed in the following sections.
Cerebral Vein and Sinus Thrombosis
Thrombosis in the cerebral vein and sinus thrombosis is distinguished by its occurrence in young adults and children, its predominance in the female, and its anat omy. Blood from the cerebral veins drains into various sinuses, which become confluent and in tum empty into the internal jugular vein. Thrombosis of the cerebral veins causes edema, venous infarction, and sometimes hemorrhage; sinus thrombosis results in intracranial hypertension due to increased venous pressure and imparted absorption of the cerebrospinal fluid. In most patients with this complication, thrombosis of both the cerebral veins and sinuses occurs.14 The most frequent location of thrombosis is the transverse sinuses (86%), followed by superior sagittal sinus (62%) and the straight sinus (18%).15 Some of the predisposing causes are discussed here.
In acute lymphoblastic leukemia (ALL), throm botic complications are frequent, with reported inci dence of 1.7 to 36.7%16.17 in children, depending on the choice ofchemotherapeutic agents, the use ofcentral venous access catheters, and the definition of thrombo sis. A recent meta-analysis 18 indicated an incidence of 5.2%. Remarkably, among those with thrombosis, about half (53.8%) p.~curred in the central nervous system, most commonly sino-venous thrombosis with cerebral infarction in 9.9%.
Although ALL is less common in adults, throm boembolic events are still a major complication with an incidence of 5.9%. In contrast to childhood ALL, deep vein thrombosis in adults occurs mostly in the lower limbs (38.9%).19 The major factors contributing to the thrombotic risk are the presence of a central venous catheter and the use of treatment protocols using L-asparaginase, which inhibits hepatic synthesis of both the coagulant and anticoagulant proteins. How ever, the recovery of these proteins following the cessation of L-asparaginase therapy takes place at different rates. The return of anticoagulant level, espe cially antithrombin, lags behind recovery of the coa § ulants, resulting in an increased thrombotic risk. 16 . 2 G-2 Because these contributory thrombogenic factors are present in both adults and children with ALL, it is intriguing why there is a predilection of thrombotic complications for the cerebral veins in children. A possible explanation is that the anatomical structure may be more prone to thrombosis in this location at a young age. This is supported by the observations that cerebral sino-venous thrombosis is more common in neonates than in young children. 23 Cerebral venous and sinus thrombosis are also the preferred sites of thrombosis in other hypercoagulable states 14 ,24 (Table 1) . Among women with cerebral venous and sinus thrombosis, the ~redominant causes are the use of oral contraceptives 21 ,25 6 and pregnancy, especiallI in the third trimester and during the peripartum period. 2,27 Among persons with inherited thrombophilia, cerebral venous thrombosis is common in those with the pro thrombin G20210A mutation 26 and in individuals with hyperhomocysteinemia due to the methylene tetrahydro folate reductase C677T gene polymorphism 14 ,28,29 (although the evidence for the latter is weak). It is also seen in heparin-induced thrombocytopenia. 30
In paroxysmal nocturnal hemoglobinuria (PNH), thrombosis is a major complication and cause of 33 death.
-
Several factors account for the increased risk of thrombosis. In additional to the thrombogenic effects of massive hemolysis and platelet activation, the fibrinolytic balance is perturbed. Due to the absence of GPI-anchoring protein for the urokinase receptor (uPAR) in PNH clones ofleukocytes, there is an excess 45 Following the ad ministration ofgonadotrophic hormones, the stimulated ovaries produced more estrogen. The drainage of the abdominal lymphatics with high estrogen content into the thoracic duct, which ends in the right subclavian vein at the junction with the right jugular vein, has been suggested to be a contributory factor. 42 , 46 The prophy lactic use of low molecular weight heparin is recom mended, but on occasions, it was unable to prevent OHSS in some patients. 43
Lower Extremity Deep Vein Thrombosis
Most major venous thrombotic events take place in the deep veins of the lower extremities. The causative factors are the nature of the anatomical structure and the characteristics of blood flow. Venous return requires the normal function of multiple valves. The formation of a thrombus usually starts in the valve pockets, where there is stagnant flow, anoxia, and deposits of platelets and leukocytes. 47 -49 At the apex of the valve pocket, there is often a preexisting microthrombus. 5o In the event of immobilization, an ensuing stasis of blood flow enables thrombus extension into the main channel of the veins. This can occur without the presence ofa hypercoagulable state. Prophylactic antithrombotic measures are thus needed, even in healthy subjects during periods of im mobilization, and are especially essential in patients with an underlying prothrombotic risk
Splanchnic Vein Thrombosis
Thrombosis in the splanchnic vasculature may occur in portal, mesenteric, and hepatic veins, the latter causing the Budd-Chiari syndrome. In the latest meta-analysis of published data involving 241 patients with splanchnic vein thrombosis (SVT), bcr/abl-negative myeloprolifer ative disorders (MPDs), as identified by the presence of the Janus kinase 2 (JAK2) V617F somatic mutation (JAK2V617F), were found in 45% of those with Budd-Chiari syndrome and in 34% of patients with portal vein thrombosis. 51 This supports earlier reports of the presence of the JAK2V617F mutation in 29.4% of portal vein thrombosis and 42.8% of SVT patients without overt manifestations ofMPD. 52 JAK2 mediates the effects of hematopoietic cytokines such as erythro poietin and granulocyte colony-stimulating factor. The JAK2V617F mutation results in a gain offunction and is believed to enhance proliferation of hematopoietic pro genitor cells in MPDs. 53 The mutant is found in '"'-'95% cases of polycythemia vera and at least 50% of patients with essential thrombocytosis. In both types of MPDs, both arterial and venous thrombosis are common com plications. 5 4-56 In the recent European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) study,55,57 low-dose aspirin was found to be effective in reducing thrombotic complications, suggesting a prothrombotic risk conferred by platelets. Numerous studies suggest that polycythemia vera and essential thrombocytliemia are associated with a hypercoagulable state, as evidenced by platelet and endothelial activa tion. 58 ,59 In essential thrombocythemia, platelets were also found to be more sensitive to activation. 58 ,59 Leu kocytes, polymorphonuclear neutrophils in particular, were also implied because they were found to be acti vated and to form aggregates with platelets in both essential thrombocythemia and polycythemia vera.
6O
Lately, the concept that an elevated hematocrit and/or a high platelet count are thrombogenic has been chal lenged. For example, recent studies have failed to dem onstrate a correlation between the thrombotic event and an increased hematocrit,61 elevated platelet count,61 or leukocytosis. 62 However, these data are at odds with a recent Norwegian studl 3 and need to be confirmed in additional studies. In any case, one might consider another contributory factor to the thrombogenesis in MPD: endothelial dysfunction at the vascular sites affected. There is indirect evidence of endothelial dys function and activation, including changes in plasma levels of fibrinogen, von Willebrand factor (VWF), soluble thrombomodulin, and plasminogen activator inhibitor 1 (PAI_1}. 64 Although arterial thrombosis is more common than venous thrombosis in MPDs, it is unexplained why thrombosis at unusual sites such as splanchnic veins is frequently seen. Because the JAK2V716F mutation in hematopoietic cells is increased in SVT,51 and this mutation is believed to cause endothelial dysfunction, one can postulate that this mutation may occur in the endothelial cells located in the splanchnic venous endo thelium. As both the hematopoietic cells and endothelial cells can be sharing a common progenitor cell,65 it is likely that the JAK2V617F mutation occurs in both lineages. In fact, some patients withJAK2V617F muta tion may develor SVT before hematological manifesta tions take place. 1,66 In recent study, Sozer et al,67 using laser capture micro-dissection followed by polymerase chain reaction (PCR) and real time (RT)-PCR, exam ined the endothelial cells lining the terminal hepatic venules. In two of three patients with polycythemia vera complicated by SVT, the hepatic venular endothelial cells showed homozygosity for the JAK2V617F muta tion. In two other nonpolycythemic control patients with hepatoportal sclerosis complicated by portal vein throm bosis, their endothelial cells showed exclusively the wild type JAK2. These findings open the way for more future studies, exploring the extent of this mutation in the endothelial cells in other locations of the body.
Paroxysmal Nocturnal Hemoglobinuria
As previously mentioned, thrombosis is the major cause of morbidity and mortality in PNH. Among the throm boembolic events, splanchnic vein thrombosis accounts for 63.9%.24,25,27,68 The thrombotic risk in this disorder was discussed earlier in the section on cerebral vein thrombosis.
Sinusoidal Obstruction Syndrome/Hepatic Veno-Occlusive Disease
In sinusoidal obstruction syndrome (SOS) or hepatic veno-occlusive disease (VOD), the hepatic venular and sinusoidal endothelium in zone 3 of the hepatic acinus is occluded by subendothelial edema, red cell extravasation, 72 and fibrin deposition. 69 -Originally termed hepatic veno-occlusive disease, the name was changed because central vein thrombosis occurs in only 55% of mild disease and in 75% of the severe cases. This is a remarkable example of site-specific endothelial damage leading to vascular occlusion and thrombosis. There are two major causes of the damage. One is associated with chemotherapy or radiation, used in myeloablative ther apy. It is also seen in chemotherapy with agents such as gemtuzumab ozogamicin (Mylotarg), actinomycin D, dacarbazine, cytosine arabinoside, mitramycin, 6-thio guanine, and urethane. The other cause in non-Western countries is the ingestion of diet contaminated by pyr rolizidine alkaloids. SOSNOD responds poorly to treatment with anticoagulants. However, defibrotide was found to be effective in about a third of the cases. 73 Defibrotide is a polydisperse oligonucleotide, which binds to the endothelium via adenosine receptors Al and A2, has antithrombotic, anti-ischemic, anti-adhe sive, anti-inflammatory, and thrombolytic properties, through binding to the liver endothelium via adenosine receptors Al and A2.
Ovarian Vein Thrombosis
Ovarian vein thrombosis is an uncommon complication seen in delivery?4,75 Sepsis is believed to playa key role.
Microvascular Thrombosis
In a hypercoagulable state, thrombosis often initiates in the microvasculature and then readily extends to larger venous channels. However, in two conditions, warfarin necrosis and heparin-induced thrombocytopenia, the microvascular occlusion is not only the presenting clin ical feature but often remains as the only site of vascular involvement.
In warfarin necrosis, the site ofthrombosis is in the skin and locations with abundant adipose tissues, com monly in the breast, abdomen, and thigh?6-80 In the involved tissues, diffuse microthrombi in the capillaries and venules are present initially in the dermis and sub cutaneous tissues. Subsequendy, the thrombosis can ex tend to larger veins and can produce large areas ofnecrosis. This is an uncommon complication of oral anticoagulant therapy that occurs within 3 to 10 days ofthe initiation of therapy. It ii;i qelieved to be due to inhibition ofthe hepatic synthesis of p~otein C, protein S, antithrombin, and the other clotting factors (TI, VII, IX, X) by warfarin. Protein C and factor VII have a shorter half-life compared with that of the other vitamin K-dependent coagulation fac tors, especially factor X. As a result, a rapid fall in protein C takes place leading to a transient imbalance between the anticoagulant and the procoagulant proteins. 81 Such a hypercoagulable state is exacerbated in patients with a preexisting protein C deficiency.79 This hypothesis is supported by our own observations that 11 of 13 patients who had recovered from warfarin necrosis had abnormally low levels of functional protein C in their plasma. 80 However, other mechanisms may be responsible for war farin necrosis because it has been seen in patients without protein C deficiency.
Heparin-Induced Thrombocytopenia
The diagnosis of this condition is suspected when the platelet count falls significandy after initiation of hep arin. 82 Thrombotic events are most commonly arterial with the finding ofa platelet-rich "white clot." However, the condition starts with microvascular lesions caused by platelet aggregates, formed as the result of an immuno globulin (Ig)G autoantibodylheparin-platelet factor 4 complex. The micro thrombi then extend to form larger lesions. There is evidence suggesting that this IgG complex is not only present in the platelet thrombi but is also deposited on the endothelial surface at the site of thrombosis. 85 Although most organs are affected in advanced stages of the disease, the microvasculature in the brain, kidneys, skin, and myocardium is most commonly involved; that in the liver and lungs is least commonly affected. Among the various pathogenic factors for TTP is endothelial injury. In vitro studies have revealed that plasma from autoimmune TTP patients can cause aportosis of micro vascular endothelial cells (MVECs).9 Furthermore, MVECs derived from the brain, kidneys, and skin are most sensitive to the TTP plasma, whereas those derived from lung and liver are not. More recently, some dis tinguishing features of the sensitive versus nonsensitive MVECs were found. 92 ,93 In the TTP-sensitive MVECs, apoptosis in the presence of TRAIL (tumor necrosis factor related apoptosis-inducing ligand), along with interferon-'Y, was enhanced. This was due to a lack. of inhibition ofthe caspase-8 pathway. Ubiquitination ofan inhibitor of apoptosis, c-FLIP (a FLICE-like inhibitory protein), leads to its degradation ofthis proteosome. This is not the case with the nonsensitive MVECs derived from the lung. However, c-FLIP silencing by anti-FLIP siRNA rendered the lung MVECs susceptible to apop tosis. Such findings provide one explanation for the site specificity ofTIP lesions. What is still an enigma is the link between the endothelial injury and the development of autoantibodies against ADAMTS 13. Because pertur bation of the complement system occurs in the closely related HUS, it is postulated that complement-induced endothelial injury may also playa part in TIP.94
Hemolytic Uremic Syndrome
There are two forms of hemolytic uremic syndrome (HUS): the Shiga toxin induced form and the atypicaV recurrent form. 9 ,96 In the Shiga toxin induced form, the toxin binds to a receptor (Gp3) in the endothelial cells, causing the injury. 97 The increased inflammatory cyto kines caused by the Shiga toxin results in an upregulation of Gp3 expression the endothelial cells. However, in the atypical HUS, injury to the endothelial cells is induced by the terminal complement complex, C5b-9. In both forms of HUS, the renal endothelial cells are most susceptible to the respective injury, with clinical mani festation of acute impairment of renal function. 98 In volvement of the other organs is not common, although a small number of patients may have neurological changes. The human brain MVECs are also susceptible to apoptosis induction by Shiga toxin 1 and Shiga toxin 2. 99 The predilection of renal MVEC to this injury has not been adequately explained.
Miscellaneous
Disseminated intravascular coagulation (DIC) is usually associated with endothelial cell damage from bacterial toxins and phYl:1.ical and other chemical injuries, but extensive microthrombi formation is not common and requires additional comorbid disorders such as cata strophic antiphospholipid syndrome lOO or extensive mi crovascular occlusion by agglutinated red blood cells in cold hemagglutinin disease 101 and in malaria. 102 The renal arterioles are most susceptible to thrombosis, followed by small vessels in the brain and mesentery. In erythromelalgia, seen mostly in MPDs, platelet acti vation and thrombi formation are the cause of the painful manifestations, which are promptly relieved by antiplatelet drugs. 103 
Arterial Thrombosis
In contrast to venous thrombosis, most arterial throm bosis occurs in arteries with preexistent disease. Endo thelial phenotypes differ between arteries and veins. Arterial thrombus is rich in platelets, whereas venous thrombus contains mostly fibrin and red cells. Arterial thrombi are formed under conditions of high or aberrant blood How, but a venous thrombus begins with a stagnant How. The site ofarterial thrombosis is mostly determined by the distribution of atherosclerotic lesions, which is in turned influenced by the pattern of blood How. Less commonly, arterial thrombosis occurs in the absence of atherosclerosis (e.g., in systemic lupus erythematosus, affecting cerebral arteries; in polyarteritis nodosa, affect ing muscular arteries; in Takayasu's arteritis, affecting aortic arch; and in giant cell arteritis affecting the carotid, temporal, and vertebral arteritis) (Table 1 ). However, recent clinical observations indicate that both arterial and venous thrombosis share many common predisposing features 104 and the fcattem of similarity between the two has emerged. lOS. 06 A common feature is the asso ciation with metabolic syndrome,107.I08 obesity/09·110 smoking,l09.IlO hypertension/ lo and hyperlipide mia. Ill • Il2 In addition, the markers of arterial thrombosis such as increased levels offibrinogen, VWF, PAl-I, and inflammatory cytokines can also be found in venous thrombosis.H 3
CI.INICAL OBSERVATIONS ON SITE OF BLEEDING
Other than direct injury to a blood vessel, the site of bleeding in a patient with general bleeding diathesis can also show a higher incidence in certain locations. The site predilection is much less pronounced than in the case of thrombosis. Table 2 shows some of the locations.
Intracranial Hemorrhage
The major risk factors for intracerebral hemorrhage (ICH) are hypertension, high alcohol consumption, smoking, hypercholesterolemia, diabetes mellitus, and male gender. 114 Hemostatic risk factors have also been identified, including high tissue plasminogen activator (tPA)/PAI-1 complex and low VWF. The latter shows a synergistic interaction with hypertension. lls Reduced platelet function portends a worse prognosis. 116 Several diseases with general bleeding diathesis but with a higher incidence of ICH are discussed next.
Acute Promyelocytic Leukemia
In acute promyelocytic leukemia (APL) (FAB classifi cation: M3), there is a failure of differentiation of the myeloid lineage resulting in the arrest at the promyelo cyte stage. On presentation, the patient is in a marked hypercoagulable state, due to an increased expression of tissue factor and of a cancer procoagulant by the leuke mic promyelocytesY7-l20 This manifests as DIC with bleeding complications. In multiple clinical trials, the major cause of early deaths is bleeding. Among these, ICH is the most common form, accounting for 65 to 85% of early deaths.12l.l22 The high risk of bleeding is due to multiple factors, including thrombocytopenia, hypofibrinogenemia from DIC, increased fibrinolysis with increased tPA and uPA, and decreased P AI-1 and crrantiplasmin.l20.l23 In addition, there is an in crease in annexin II on the leukemic promyelocytes.
Annexin II is a co-receptor for plasrnino §en and for tPA, and it facilitates plasmin generation. 1 4 However, the high incidence of ICH requires added explanation. We studied the presence of annexinII in human endo thelial cells in vitro and observed that it is constitutively expressed in much higher amounts in the cerebral micro vascular endothelial cells than in endothelial cells derived from other parts of the body.12S This finding offers one explanation why ICH is more common than bleeding at other sites. It also provides one reason for the higher incidence ofICH seen in thrombolytic therapy with tPA than with other fibrinolytic agents. In APL, in spite of these findings of increased fibrinolysis, the use of the antifibrinolytic agent tranexarnic acid did not prevent this complication in one nonrandomized clinical trial. 126 In vitro treatment of the APL cell line, NB4, with all trans retinoic acid (ATRA) resulted in prompt down regulation ofannexin II. Likewise, APL patients treated with ATRA also demonstrated reduced fibrinolytic activity in blood. l23 We recently observed that micro particles bearing annexin II are found in the blood of patients with APL. They were also reduced by ATRA treatment.
Acute Lymphoblastic Leukemia
Hemorrhagic comflications is a major cause of death in childhood ALL. 12 .128 As in the case ofAPL, two thirds of the bleeding events in ALL were also ICH.
Thrombolytic Therapy ICH is an uncommon but important complication in thrombolytic therapy when used for pulmonary embo 129l:fO dial '_1:
myocar lIllarct1on, an ISC emlC stroke. 132 In pulmonary embolism, the rate of ICH is 1.7% in clinical trials using tPA, but it is believed to be close to 3.0% in a large registryllO and is lower with other thrombolytic agents. In myocardial infarction, the rate is <1%, but is higher (1.7%) with tPA in elderly pa tients.1l4.131 In stroke, the incidence of ICH is much higher, ranging from 7.7% to 22.3% in different clinical trials,132 with higher rates when treatment was begun later than 3 hours of onset of the stroke. An interesting additional risk factor is a low P AI-1Ieve1. 133 ,134 In ICH complicating tPA therapy, the bleeding usually occurs in the absence of bleeding elsewhere in the body and takes place a day or so after the treatment, long after circulat ing tPA has been cleared. One explanation may be the fact that annexin II is hijher in the brain microvascula ture, as discussed earlier. 06
Diffuse Alveolar Hemorrhage
In both APL and ALL, pulmonary hemorrhage was also common,126,135 but second to ICH. Diffuse alveolar hemorrhage is also seen in other diseases as listed in Table 3 . In neonates and in premature births, anoxia is a major risk factor. It is also seen in Goodpasture's Adhesive molecules P-selectin; E-selectin PECAM-l; ICAM-l;VCAM-l PAR, protease-activated receptor; ADAMTS 13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, Member 13; PAl, plasminogen activator inhibitor; ADPase, adenosine dipho sphatase; PECAM, platelet endothelial cell adhesion molecule; ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule.
syndrome, Wegener's granulomatosis, and systemic lu pus erythematosus.
Adrenal Hemorrhage
This is a complication seen in long-term anticoagulant therapy, in the postoperative period, in the antiphos pholipid-antibody syndrome, in heparin-induced thrombocytopenia, or in the setting of severe physical stress and multiorgan failure. 136 The hemorrhage can sometimes De the result of microvascular thrombosis. This organ is prone to these complications on account of its unique venous anatomy and rich arterial supply37 and because it is high in catecholamine concentration. 8
Retroperitoneal Hemorrhage
This complication is seen in patients recelVlng anti coagulation,138 most often with warfarin but also with heparin. It also occurs after abdominal trauma, after rupture of aneurysm, and misadventure with transvas cular catherization. Age is a risk factor, likely related to presence of more advanced atherosclerotic lesions in the eldedy. 139 The bleeding usually occurs in multiple small arteries and can be readily demonstrated by computed tomography (CT) scan with contrast, and bleeding can be controlled by embolization. 138
Hemarthrosis
In patients with hereditary coagulation defects, bleeding into the joints is perhaps the most frequent long-term complication. One explanation for a higher bleeding rate into this location is that the synovial membrane lacks "ch' fib' l ' .. 140 141 procoagulants but IS n m rmo yttc act1V1ty. .
THE BASIS FOR HETEROGENEITY IN THROMBOTIC AND BLEEDING SITES Expression of Hemostatic and Fibrinolytic Factors
Endothelial expression of hemostatic and fibrinolytic factors is not consistent across the vasculature. For example, although most factor YIn is present in hep atocytes and in renal glomerular cells by mRNA analysis, its expression in the endothelium is limited to liver sinusoids. 142 In contrast, the mRNA of VWF is mostly expressed in veins, with the exception of the pulmonary veins, but is largely absent in arteries, with the exception of the distal aorta and pulmonary arteries, and has little " ill' [143] [144] [145] [146] [147] species.
believed to play a role in early atherogenesis. 149 The components of the fibrinolytic system are also distrib uted unevenly.150,lSl Such heterogeneity may explain many clinical observations of the site of thrombosis in patients with a hypercoagulable state or of hemorrhage in bleeding diathesis.
Variable Response to Stimuli: Inflammatory Cytokines, Blood Flow, Drugs, and Toxins ( Fig. 1 ) Under physiological conditions, there is a hemostatic balance in the endothelium, maintained by both pro thrombotic and antithrombotic factors ( Table 3 ). The prothrombotic factors include tissue factor, encrypted on the cell membrane; VWF, stored in Weibel Palade bodies; protease-activated receptors (PAR-l and PAR 4), serving as thrombin receptors; thromboxane A2 and platelet-activating factor, enhancing platelet activation; PAl-l, which inhibits fibrinolysis; and adhesive mol ecules, P-selectin (CD62P), E-selectin (CD62E), PECAM-l (CD31), ICAM-l (CD54), and VCAM 1 (CD106), which attract leukocytes to the endothelial surface, bringing with them reactive oxygen species (ROS) and procoagulants. In contrast, there are an tithrombotic factors consisting of tissue factor pathway inhibitor, blocking activated tissue factor; protein C and protein S, inhibiting factors V and VIII; throm bomodulin that activates protein C and protein S; endothelial protein C receptor; heparan, inhibiting factors Xa and IIa (thrombin); nitric oxide synthetase, producing nitric oxide; prostacyclin, inhibiting platelet activation and promotes vasodilation; ADAMTS13, cleaving VWF; ecto-ADPase, inhibiting platelet func tion; and members of the plasminogen-plasmin system, which includes tPA, uPA, uPA receptor, and annexin A2.
Upon stimulation, this balance is switched to favor hemostasis, as nature's defense mechanism to conserve blood loss (Fig. 2) . The most common stimulus is the inflammatory cytokines. TNFo: and interIeukin (IL)l produce multiple changes in the endothelium, with upregulation of tissue factor and adhesive mole cules. They up regulate many of the prothrombotic factors, such as tissue factor, but also the adhesive molecules. The latter in tum attract leukocytes to the endothelium, and along with them ROS and procoagu lants. Other stimuli include altered blood flow with increased shear stress, drugs, and toxins. Depending on the nature and the degree of stimulation, a potential risk of thrombosis ensues. However, certain stimuli can produce a bleeding tendency. An example is increased fibrinolytic activity, which can result from ~hysical stress such as exercise and surgical operations. l 2-154 This is believed to account for severe hemorrhagic complica tions during surgery. 153, 154 The resulting response in the direction of the hemostatic balance, however, is not uniform throughout the vasculature. The expression of the prothrombotic and antithrombotic factors is also uneven in different locations.
Role of Altered Flow Dynamics
Under shear stress, the configuration of the molecules of both VWF and of ADAMTS13 are changed to expose their respective active reactive sites. Thus, in areas of high shear stress, VWF reacts maximally with the Gplb on platelet membrane and produces the greatest platelet activation. This principle has been used to explain the initial locations of atheroma. It is also applied in attempts to design drugs such as anti-Gplb antibodies that inhibit platelet aggregation selectively in places with high shear stress, thus avoiding a generalized bleeding risk. anon. ey carry 0 procoa ant an anticoagulant proteins and components of the plasmi nogen-plasmin system. They also carry adhesive mole cules and cytokines. In healthy individuals, circulating MPs are mosdy derived from platelets, but a small numbers are from monocytes, neutrophils, and endothe lial cells. In disease, additional MPs are derived from tumor and leukemic cells and from atheromatous pla ques. Increased tissue factor-bearing MPs have been associated with thromboembolic complications in many diseases, including various types of cancer, anti phospholipid syndrome, sickle cell disease, diabetes, and systemic inflammatory disorders. In inflammatory states, MPs derived from leukocytes contain P-selectin glyco protein ligand (PSGL)-l, enabling them to attach to injured endothelial cells that express P-selectin. 159 Like wise, MPs derived from cancer cells also carry PSGL-l and were observed to enhance thrombus formation in anirnals. 160 The thrombogenic role of the MPs is an active area of investigation because the procoagulant MPs may be another determinant in the selection of the site of thrombosis.
Role of Microparticles

CONCLUSION
The acceptance of the concept of endothelial hetero geneity leads to a better understanding of the patho genesis of thrombotic and bleeding disorders. In our current understanding of the pathogenesis of bleeding and thrombosis, there is a lack of adequate explanation for the predilection of bleeding or thrombosis to specific sites of the vasculature. Thus this topic provides a fertile field for further investigations. At present, the concept helps to improve diagnostic approaches to many diseases presenting with thrombosis or bleeding at specific sites. Examples include the high incidence of myeloprolifer ative disorders in splanchnic vein thrombosis. Another example is seen in the presentation of acute idiopathic TTP as neurological and renal manifestations. This concept can also provide directions for investigation into the cause of thrombosis or bleeding that are limited to specific sites. In addition, drug development for SEMINARS IN THROMBOSIS AND HEMOST ASISNOLUME 36, NUMBER 3 2010 treating thrombosis and bleeding can be better aimed at site-directed therapy. This topic is discussed in detail in another article in this issue of Seminars in Thrombosis and Hemostasis by Carnemolla et al. 161 It also dispels the notion of "one drug treats all." 
